BioSpace News Archive

Imara Inc. announced that Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara, will present at the H.C. Wainwright BioConnect 2022 Virtual Conference being held January 10–13, 2022.

Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases (i.e. COVID-19), today announced that Uri A. Lopatin, M.D., Chief Executive Officer, will present a company overview at the 40th Annual J.P. Morgan Healthcare Conference.

Medicenna Therapeutics Corp., a clinical stage immuno-oncology company, announced that company management will be participating in the following virtual investor conferences taking place in January 2022.

Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), today reported detailed positive data from the global Phase 2b clinical trial of CBP-201 administered subcutaneously (SC) to adult patients with moderate-to-severe atopic dermatitis (AD) (WW001) (NCT04444752).

Anavex Life Sciences Corp. announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will present at the H.C. Wainwright Virtual BioConnect 2022 Conference being held January 10-13, 2022.

Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today provided a corporate update available on the Company’s website.

Autolus Therapeutics plc today announced that they are scheduled to deliver a corporate presentation at the following virtual conferences: Dr. Christian Itin, Chief Executive Officer, will present at the 40th annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 8.15 am ET.

SAB Biotherapeutics announced that Eddie J. Sullivan, PhD, co-founder, president, and CEO, will present at the H.C. Wainwright BioConnect Virtual Conference occurring January 10-13, 2022.

Leap Therapeutics, Inc. announced that Douglas E. Onsi, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright BioConnect 2022 Conference, being held virtually on January 10-13, 2022.

The drug is mostly used to treat toxoplasmosis in pregnant women because the drug reduces the chances of infection that can be caused to an unborn baby.